JP2017531693A - １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン - Google Patents

１種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン Download PDF

Info

Publication number
JP2017531693A
JP2017531693A JP2017538177A JP2017538177A JP2017531693A JP 2017531693 A JP2017531693 A JP 2017531693A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017538177 A JP2017538177 A JP 2017538177A JP 2017531693 A JP2017531693 A JP 2017531693A
Authority
JP
Japan
Prior art keywords
vaccine
antigen
seq
population
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017538177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531693A5 (enExample
Inventor
エリック ブラエニング
エリック ブラエニング
クラウス フリュー
クラウス フリュー
ルイス ピッカー
ルイス ピッカー
ベット ティー．エム． ケルバー
ベット ティー．エム． ケルバー
ジェイムズ タイラー
ジェイムズ タイラー
エミリー マーシャル
エミリー マーシャル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Original Assignee
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University filed Critical Oregon Health & Science University
Publication of JP2017531693A publication Critical patent/JP2017531693A/ja
Publication of JP2017531693A5 publication Critical patent/JP2017531693A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017538177A 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン Pending JP2017531693A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462059506P 2014-10-03 2014-10-03
US201462059497P 2014-10-03 2014-10-03
US62/059,506 2014-10-03
US62/059,497 2014-10-03
PCT/US2015/054067 WO2016054654A1 (en) 2014-10-03 2015-10-05 Hiv vaccines comprising one or more population episensus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020170852A Division JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Publications (2)

Publication Number Publication Date
JP2017531693A true JP2017531693A (ja) 2017-10-26
JP2017531693A5 JP2017531693A5 (enExample) 2018-11-15

Family

ID=55631703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017538177A Pending JP2017531693A (ja) 2014-10-03 2015-10-05 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020170852A Active JP7212020B2 (ja) 2014-10-03 2020-10-09 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
JP2023003194A Active JP7441340B2 (ja) 2014-10-03 2023-01-12 １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン

Country Status (16)

Country Link
US (3) US10894078B2 (enExample)
EP (1) EP3200878B1 (enExample)
JP (3) JP2017531693A (enExample)
KR (1) KR102633096B1 (enExample)
CN (1) CN108064181A (enExample)
AU (2) AU2015327797A1 (enExample)
CA (1) CA2963573C (enExample)
EA (1) EA201790680A1 (enExample)
HK (1) HK1254806A1 (enExample)
IL (1) IL251469B2 (enExample)
MA (1) MA40783A (enExample)
MX (3) MX391149B (enExample)
SG (1) SG11201702729YA (enExample)
UA (1) UA126890C2 (enExample)
WO (1) WO2016054654A1 (enExample)
ZA (1) ZA202206809B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116847882A (zh) * 2021-01-14 2023-10-03 吉利德科学公司 Hiv疫苗及其使用方法
JP2024504298A (ja) * 2021-01-14 2024-01-31 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US20210317192A9 (en) * 2019-05-29 2021-10-14 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
BR112022003474A2 (pt) 2019-08-29 2022-05-24 Triad Nat Security Llc Vacinas do vírus da hepatite b
CN117836311A (zh) * 2021-08-31 2024-04-05 维尔生物科技公司 用于产生cmv载体的方法
US20240384296A1 (en) 2021-08-31 2024-11-21 Vir Biotechnology, Inc. Recombinant hcmv vectors and uses thereof
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
WO2005012502A2 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
CA2539325C (en) * 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
WO2005035779A2 (en) 2003-10-10 2005-04-21 Powderject Vaccines, Inc Method
AU2005285513B2 (en) 2004-05-25 2011-02-24 Oregon Health And Science University SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
KR102511874B1 (ko) 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US20100183651A1 (en) 2007-03-30 2010-07-22 Finnefrock Adam C Broadly Representative Antigen Sequences and Method for Selection
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
JP2013507107A (ja) * 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2820035B1 (en) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
WO2014107744A1 (en) * 2013-01-07 2014-07-10 Beth Israel Deaconess Medical Center, Inc. Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
JP2017507672A (ja) 2014-02-28 2017-03-23 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 複製型組み換えアデノウイルスベクター、組成物およびこれらの使用方法
NZ728208A (en) 2014-07-16 2018-07-27 Univ Oregon Health & Science Human cytomegalovirus comprising exogenous antigens
MA40765B1 (fr) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
PL3390430T3 (pl) 2015-12-15 2020-03-31 Janssen Vaccines & Prevention B.V. Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Protein Nef", UNIPROT, JPN6019030766, 19 October 2011 (2011-10-19), ISSN: 0004280750 *
BAROUCH DAN H. ET AL., NATURE MEDICINE, vol. 16, no. 3, JPN6019030770, March 2010 (2010-03-01), pages 319 - 323, ISSN: 0004092236 *
KORBER, BETTE T. M: "LANL/NEW MEXICO CONSORTIUM HIV VACCINE DESIGN AND ANALYSIS", [ONLINE], JPN5017008659, 7 July 2014 (2014-07-07), pages 10, ISSN: 0004092234 *
NOVITSKY V. ET AL., JOURNAL OF VIROLOGY, vol. 76, no. 11, JPN6019030767, June 2002 (2002-06-01), pages 5435 - 5451, ISSN: 0004280751 *
SANTRA SAMPA ET AL., NATURE MEDICINE, vol. 16, no. 3, JPN6019030768, 21 February 2010 (2010-02-21), pages 324 - 329, ISSN: 0004092235 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116847882A (zh) * 2021-01-14 2023-10-03 吉利德科学公司 Hiv疫苗及其使用方法
JP2024504298A (ja) * 2021-01-14 2024-01-31 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP2024177497A (ja) * 2021-01-14 2024-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP2025089444A (ja) * 2021-01-14 2025-06-12 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
JP7879916B2 (ja) 2021-01-14 2026-06-24 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法

Also Published As

Publication number Publication date
CA2963573C (en) 2024-02-06
SG11201702729YA (en) 2017-04-27
US11628215B2 (en) 2023-04-18
EP3200878B1 (en) 2025-06-04
AU2021218141A1 (en) 2021-09-09
JP7212020B2 (ja) 2023-01-24
US20210046175A1 (en) 2021-02-18
IL251469B1 (en) 2023-01-01
KR102633096B1 (ko) 2024-02-02
US20170319679A1 (en) 2017-11-09
EA201790680A1 (ru) 2017-11-30
MA40783A (fr) 2017-08-08
AU2021218141B2 (en) 2024-06-06
ZA202206809B (en) 2023-11-29
US10894078B2 (en) 2021-01-19
MX2022003663A (es) 2022-04-25
UA126890C2 (uk) 2023-02-22
MX2022003664A (es) 2022-04-25
CN108064181A (zh) 2018-05-22
HK1254806A1 (zh) 2019-07-26
KR20170122711A (ko) 2017-11-06
MX2017004275A (es) 2018-01-17
JP7441340B2 (ja) 2024-03-06
IL251469B2 (en) 2023-05-01
EP3200878A4 (en) 2018-05-30
MX391149B (es) 2025-03-21
CA2963573A1 (en) 2016-04-07
BR112017006865A2 (pt) 2017-12-12
JP2023059272A (ja) 2023-04-26
AU2015327797A1 (en) 2017-05-11
WO2016054654A1 (en) 2016-04-07
NZ731173A (en) 2024-04-26
IL251469A0 (en) 2017-05-29
US20210046174A1 (en) 2021-02-18
EP3200878A1 (en) 2017-08-09
US11554168B2 (en) 2023-01-17
JP2021035946A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7441340B2 (ja) １種類または複数種類の集団エピセンサス抗原を含むｈｉｖワクチン
Sok et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice
Ondondo et al. Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection
KR102663972B1 (ko) 예비-면역화 단계가 없는 hiv 면역요법
Kulkarni et al. HIV-1 p24gag derived conserved element DNA vaccine increases the breadth of immune response in mice
JP2022101658A (ja) Ｈｉｖワクチン接種および免疫療法
BRPI0921588B1 (pt) Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral
CN113186223A (zh) 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗
US20050221285A1 (en) Method for identifying or screening anti-viral agents
Lu et al. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice
Murakowski et al. Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques
CN114729010B (zh) 乙型肝炎病毒疫苗
Sarkar et al. Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope
HK1241309A1 (en) Hiv vaccines comprising one or more population episensus antigens
HK1241309B (en) Hiv vaccines comprising one or more population episensus antigens
EA040402B1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) антигенов для популяции
Perdiguero et al. B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2
BR122021016789B1 (pt) Vacinas contra hiv-1 compreendendo um ou mais antígenos epissenso de população, usos das mesmas para proteger um indivíduo de uma infecção por hiv-1, tratar hiv-1 e induzir uma resposta de células t de memória efetoras, bem como polipeptídeo e método para projetar e produzir as ditas vacinas
BR112017006865B1 (pt) Vacina contra hiv-1 compreendendo um ou mais antígenos epissenso de população, uso da mesma para proteger um indivíduo de uma infecção por hiv-1 ou para tratar hiv-1 e polipeptídeo
HK40074198A (en) Hepatitis b virus vaccines
CN102210874A (zh) 一种hiv重组亚型dna疫苗的制备方法
Darton et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B. 1.1. 7)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200610